These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 14528163)

  • 1. [What does "power of the study" mean? How to compute the power of a study? How to compute the number of subjects needed for a trial?].
    Mélot C
    Rev Mal Respir; 2003 Sep; 20(4):602-3. PubMed ID: 14528163
    [No Abstract]   [Full Text] [Related]  

  • 2. Evaluation of the statistical power for multiple tests: a case study.
    Yeo A; Qu Y
    Pharm Stat; 2009; 8(1):5-11. PubMed ID: 18381588
    [TBL] [Abstract][Full Text] [Related]  

  • 3. How to design a clinical trial.
    Curtis BM; Barrett BJ; Parfrey PS
    Methods Mol Med; 2003; 86():475-89. PubMed ID: 12886789
    [No Abstract]   [Full Text] [Related]  

  • 4. Multiplicity-adjusted sample size requirements: a strategy to maintain statistical power with Bonferroni adjustments.
    Leon AC
    J Clin Psychiatry; 2004 Nov; 65(11):1511-4. PubMed ID: 15554764
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Analysis and importance of statistical power and sample size in empirical scientific research].
    Klimek KM
    Wiad Lek; 2008; 61(7-9):211-5. PubMed ID: 19172834
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sample size reestimation by Bayesian prediction.
    Wang MD
    Biom J; 2007 Jun; 49(3):365-77. PubMed ID: 17623342
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ALS issues in clinical trials. Statistical issues.
    Levin B
    Amyotroph Lateral Scler Other Motor Neuron Disord; 2004 Sep; 5 Suppl 1():43-5. PubMed ID: 15512870
    [No Abstract]   [Full Text] [Related]  

  • 8. Rating rater improvement: a method for estimating increased effect size and reduction of clinical trial costs.
    Cogger KO
    J Clin Psychopharmacol; 2007 Aug; 27(4):418-20. PubMed ID: 17632240
    [No Abstract]   [Full Text] [Related]  

  • 9. Studying the prevention of acute kidney injury: lessons from an 18th-century mathematician.
    Chertow GM; Palevsky PM; Greene T
    Clin J Am Soc Nephrol; 2006 Sep; 1(5):1124-7. PubMed ID: 17699335
    [No Abstract]   [Full Text] [Related]  

  • 10. [Roaming through methodology. XXXIII. Ethics of sample size estimation: less subjects needed for a one-sided than for a two-sided statistical investigation].
    Knottnerus JA; Bouter LM
    Ned Tijdschr Geneeskd; 2001 Jun; 145(22):1051-4. PubMed ID: 11414165
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sample size calculation for the Power Model for dose proportionality studies.
    Sethuraman VS; Leonov S; Squassante L; Mitchell TR; Hale MD
    Pharm Stat; 2007; 6(1):35-41. PubMed ID: 17323313
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Aspects of sample size determination and power calculation illustrated on examples from rehabilitation research].
    Kutschmann M; Bender R; Grouven U; Berg G
    Rehabilitation (Stuttg); 2006 Dec; 45(6):377-84. PubMed ID: 17123220
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of the Gould-Shih procedure for sample size re-estimation.
    Waksman JA
    Pharm Stat; 2007; 6(1):53-65. PubMed ID: 17133631
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sample size and the probability of a successful trial.
    Chuang-Stein C
    Pharm Stat; 2006; 5(4):305-9. PubMed ID: 17128428
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluating the adaptive performance of flexible sample size designs with treatment difference in an interval.
    Liu GF; Zhu GR; Cui L
    Stat Med; 2008 Feb; 27(4):584-96. PubMed ID: 17634972
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Methodology of superiority vs. equivalence trials and non-inferiority trials.
    Christensen E
    J Hepatol; 2007 May; 46(5):947-54. PubMed ID: 17412447
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Statistical significance, power and sample size--Part 2.
    Christley RM
    J Small Anim Pract; 2008 Jul; 49(7):321-2. PubMed ID: 18638056
    [No Abstract]   [Full Text] [Related]  

  • 18. Power analyses for correlations from clustered study designs.
    Tu XM; Kowalski J; Crits-Christoph P; Gallop R
    Stat Med; 2006 Aug; 25(15):2587-606. PubMed ID: 16025545
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A generalized concept of power helped to choose optimal endpoints in clinical trials.
    Borm GF; van der Wilt GJ; Kremer JA; Zielhuis GA
    J Clin Epidemiol; 2007 Apr; 60(4):375-81. PubMed ID: 17346612
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The fallacy of enrolling only high-risk subjects in cancer prevention trials: is there a "free lunch"?
    Baker SG; Kramer BS; Corle D
    BMC Med Res Methodol; 2004 Oct; 4():24. PubMed ID: 15461821
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.